Search clinical trials for: CYT005-AllQbG10

Total 91 results

Cytos Biotechnology AG

Completed

A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

House Dust Mite Allergy | Perennial Allergic Rhinoconjunctivitis

Switzerland
Cytos Biotechnology AG

Completed

Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy

Allergic Asthma | Perennial Allergic Rhinoconjunctivitis

Switzerland
Cytos Biotechnology AG

Completed

Safety and Efficacy of an Allergen Vaccine in Grass-Pollen Allergy

Hypersensitivity

Switzerland
Cytos Biotechnology AG

Completed

A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

House Dust Mite Allergy | Perennial Allergic Rhinoconjunctivitis
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients

Malignant Melanoma

Switzerland
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients

Malignant Melanoma

Switzerland
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

Malignant Melanoma

Switzerland
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

Melanoma

Germany
Cytos Biotechnology AG

Completed

Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

Perennial Allergy to House Dust Mite and/or Cat

Estonia, Latvia, Lithuania
Cytos Biotechnology AG

Withdrawn

CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids

Asthma

United States
Cytos Biotechnology AG

Terminated

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

Moderate to Severe Allergic Asthma

United States, Czech Republic, Germany, Hungary, Israel, Poland, Russian Federation, Ukraine
Cytos Biotechnology AG

Completed

CYT003-QbG10 for Treatment of Allergic Asthma Bronchial

Allergic Bronchial Asthma

Germany
Cytos Biotechnology AG

Completed

Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy

Rhinoconjunctivitis | Allergies

Estonia, Germany, Greece, Latvia, Lithuania, Romania
Cytos Biotechnology AG

Completed

Efficacy and Safety of Nicotine-Qbeta Vaccine in Smokers

Smokers

Switzerland
Cytos Biotechnology AG

Completed

Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb

Essential Hypertension
Cytos Biotechnology AG

Completed

Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension

Mild Essential Hypertension | Moderate Essential Hypertension

Switzerland
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection

Tuberculosis

United States
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the QuantiFERON-TB Test.

Tuberculosis

United States
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the QuantiFERON-TB Test.

Tuberculosis

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)

Idiopathic CD4+ T-Lymphocytopenia

United States
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Not yet recruiting

A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults

Respiratory Syncytial Virus (RSV) | RSV Infection
CStone Pharmaceuticals

Completed

A Study of CS3005 in Advanced Solid Tumors

Advanced Solid Tumor

Australia
Cytos Biotechnology AG

Completed

Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension

Hypertension

Switzerland, Germany
Cyclacel Pharmaceuticals, Inc.

Recruiting

A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma

Lymphoma | Solid Tumor, Adult

United States, Korea, Republic of, Spain
Cyclacel Pharmaceuticals, Inc.

Suspended

A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)

Leukemia | Myelodysplastic Syndrome(MDS)

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects

Healthy Volunteers

Australia
Cyclacel Pharmaceuticals, Inc.

Active, not recruiting

Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects

Healthy

United States
Gyroscope Therapeutics Limited
Novartis Pharmaceuticals

Active, not recruiting

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 (EXPLORE)

Dry Age-related Macular Degeneration

United States, Germany, United Kingdom, Spain, Poland, Australia, France, Netherlands
Gyroscope Therapeutics Limited
Novartis Pharmaceuticals

Active, not recruiting

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Dry Age-related Macular Degeneration

United States, Germany, United Kingdom, France, Spain, Australia, Poland
Cytheris SA

Terminated

Study on Interleukin-7 (CYT107) in HIV Patients (Inspire 2)

HIV

United States, Canada
Norroy Bioscience Co., LTD

Recruiting

Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients

Clear Cell Renal Cell Carcinoma Metastatic

China
Anesiva, Inc.

Completed

Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures

Coronary Artery Disease

United States
Anesiva, Inc.

Completed

Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures

Ischemia | Arterial Occlusive Diseases | Peripheral Vascular Diseases | Hyperplasia | Graft Occlusion, Vascular

United States, Canada
Revimmune
C.R.O. ReSolution Latin America S.A.

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort) (ILIAD-7-BRA)

COVID-19 | Lymphocytopenia

Brazil
Revimmune
M.D. Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Cancer Research... and other collaborators

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ) (ILIAD-7-US-O)

COVID-19 | Lymphocytopenia

United States
Cyclacel Pharmaceuticals, Inc.

Completed

A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

Cancer

United States
Suzhou Transcenta Therapeutics Co., Ltd.

Terminated

Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Cancers | Metastatic Human Papillomavirus-Related Malignant Neoplasm

United States
Revimmune
University Hospital, Limoges; Amarex Clinical Research

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort (ILIAD-7-FR)

COVID-19 | Lymphocytopenia

France
Kymab Limited

Completed

A Study of Subcutaneous KY1005 in Healthy Volunteers

Immune System Diseases

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Revimmune

Withdrawn

Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation

Umbilical Cord Blood Transplant
Cytheris, Inc.

Completed

Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant

AML | MDS | CML

United States
Revimmune
Washington University School of Medicine

Terminated

Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease (IMPULSE-7)

Mycobacterium Infections, Nontuberculous

United States
Revimmune
Washington University School of Medicine; Amarex Clinical Research

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ) (ILIAD-7-US-I)

COVID-19 | Lymphocytopenia

United States
Revimmune
Amarex Clinical Research

Terminated

InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort (ILIAD-7-UK)

COVID-19 | Lymphocytopenia

United Kingdom
Wuxi No. 4 People's Hospital

Not yet recruiting

Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET Imaging in Patients With CLDN18.2 Positive Solid Tumors

Solid Tumor, Adult

China
Kymab Limited

Completed

A Study of KY1005 in Healthy Volunteers

Immune System Diseases

Netherlands
Pearl Therapeutics, Inc.

Completed

PT003 MDI Dose Confirmation Study

Chronic Obstructive Pulmonary Disease

United States
Gyroscope Therapeutics Limited
Novartis Pharmaceuticals

Active, not recruiting

FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

Eye Diseases | Macular Degeneration | Retinal Degeneration | Geographic Atrophy | Dry Age-related Macular Degeneration | Retinal Disease | Macular Atrophy

United States, United Kingdom
HK inno.N Corporation

Unknown

A Study to Evaluate Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 in Healthy Male Subjects

Healthy

Korea, Republic of
Kymab Limited

Completed

A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic

Germany, Poland, Spain, United Kingdom

Search clinical trials for: CYT005-AllQbG10

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations